Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 12/20 | 0.45 |
| ▸ | F10 | P00742 | 5/20 | 0.43 |
| ▸ | FPR1 | P21462 | 10/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361301 | 0.86 | FPR2 (0.44) | FPR2F10FPR1 | |
| SCHEMBL6361948 | 0.86 | FPR2 (0.48) | FPR2F10FPR1 | |
| SCHEMBL6366526 | 0.84 | F10 (0.56) | FPR2F10FPR1ALDH1A1LMNA | |
| SCHEMBL5375722 | 0.84 | ALDH1A1 (0.46) | FPR2F10FPR1ALDH1A1 | |
| SCHEMBL5720791 | 0.84 | F10 (0.56) | FPR2F10FPR1ALDH1A1LMNA | |
| SCHEMBL6367603 | 0.83 | FPR2 (0.60) | FPR2F10FPR1ALDH1A1 | |
| SCHEMBL5936070 | 0.82 | F10 (0.46) | FPR2F10FPR1 | |
| SCHEMBL6362460 | 0.82 | F10 (0.58) | FPR2F10FPR1 | |
| SCHEMBL6363124 | 0.82 | F10 (0.57) | FPR2F10FPR1 | |
| SCHEMBL6361333 | 0.82 | ALDH1A1 (0.48) | FPR2F10FPR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059726-A1 | Pyrrolidine-2-ones as factor xa inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059726-A1 | Pyrrolidine-2-ones as factor xa inhibitors | TFPI, F2, SERPINC1 | FPR2 371/4885F10 7/4885FPR1 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.